KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Current Deferred Revenue: 2016-2025

Historic Current Deferred Revenue for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $320.0 million.

  • Moderna's Current Deferred Revenue fell 32.49% to $320.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $320.0 million, marking a year-over-year decrease of 32.49%. This contributed to the annual value of $211.0 million for FY2024, which is 67.59% down from last year.
  • Moderna's Current Deferred Revenue amounted to $320.0 million in Q3 2025, which was up 13.07% from $283.0 million recorded in Q2 2025.
  • Moderna's 5-year Current Deferred Revenue high stood at $8.5 billion for Q3 2021, and its period low was $183.0 million during Q1 2025.
  • Over the past 3 years, Moderna's median Current Deferred Revenue value was $617.0 million (recorded in 2024), while the average stood at $790.7 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first spiked by 3,743.45% in 2021, then crashed by 75.99% in 2023.
  • Over the past 5 years, Moderna's Current Deferred Revenue (Quarterly) stood at $6.9 billion in 2021, then crashed by 60.53% to $2.7 billion in 2022, then crashed by 75.99% to $651.0 million in 2023, then crashed by 67.59% to $211.0 million in 2024, then crashed by 32.49% to $320.0 million in 2025.
  • Its Current Deferred Revenue was $320.0 million in Q3 2025, compared to $283.0 million in Q2 2025 and $183.0 million in Q1 2025.